KR100968141B1 - 세포 배양물에서 바이러스의 증식 방법 - Google Patents

세포 배양물에서 바이러스의 증식 방법 Download PDF

Info

Publication number
KR100968141B1
KR100968141B1 KR1020047003711A KR20047003711A KR100968141B1 KR 100968141 B1 KR100968141 B1 KR 100968141B1 KR 1020047003711 A KR1020047003711 A KR 1020047003711A KR 20047003711 A KR20047003711 A KR 20047003711A KR 100968141 B1 KR100968141 B1 KR 100968141B1
Authority
KR
South Korea
Prior art keywords
virus
cells
medium
culture
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020047003711A
Other languages
English (en)
Korean (ko)
Other versions
KR20050027164A (ko
Inventor
포르로프위르겐
프레크히리스티안
뤼벤홀게르
그리게르센엔스-페테르
Original Assignee
히론 베링 게엠베하 운트 콤파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 히론 베링 게엠베하 운트 콤파니 filed Critical 히론 베링 게엠베하 운트 콤파니
Publication of KR20050027164A publication Critical patent/KR20050027164A/ko
Application granted granted Critical
Publication of KR100968141B1 publication Critical patent/KR100968141B1/ko
Assigned to 노파르티스 파르마 아게 reassignment 노파르티스 파르마 아게 권리의 전부이전등록 Assignors: 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하
Assigned to 노파르티스 아게 reassignment 노파르티스 아게 권리의 전부이전등록 Assignors: 노파르티스 파르마 아게
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020047003711A 2001-09-12 2002-09-11 세포 배양물에서 바이러스의 증식 방법 Expired - Lifetime KR100968141B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10144903A DE10144903A1 (de) 2001-09-12 2001-09-12 Vermehrung von Viren in Zellkultur
DE10144903.8 2001-09-12

Publications (2)

Publication Number Publication Date
KR20050027164A KR20050027164A (ko) 2005-03-17
KR100968141B1 true KR100968141B1 (ko) 2010-07-06

Family

ID=7698761

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047003711A Expired - Lifetime KR100968141B1 (ko) 2001-09-12 2002-09-11 세포 배양물에서 바이러스의 증식 방법

Country Status (16)

Country Link
US (1) US20050118698A1 (https=)
EP (1) EP1427817B1 (https=)
JP (2) JP2005502357A (https=)
KR (1) KR100968141B1 (https=)
AT (1) ATE466932T1 (https=)
AU (1) AU2002338666B2 (https=)
BR (1) BR0212469A (https=)
CA (1) CA2456561A1 (https=)
CY (1) CY1110716T1 (https=)
DE (2) DE10144903A1 (https=)
DK (1) DK1427817T3 (https=)
ES (1) ES2345606T3 (https=)
NZ (1) NZ532203A (https=)
PT (1) PT1427817E (https=)
SI (1) SI1427817T1 (https=)
WO (1) WO2003023025A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537760A (ja) * 2004-05-20 2007-12-27 アイディー バイオメディカル コーポレイション インフルエンザワクチンを製造するためのプロセス
ATE489965T1 (de) 2004-09-09 2010-12-15 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
ES2525518T3 (es) 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
JP2009514844A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP4585610A3 (en) * 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
EP2615167A1 (en) 2006-09-15 2013-07-17 MedImmune, LLC Method for eliminating DNA contaminants from viral preparations
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8785173B2 (en) 2008-09-24 2014-07-22 Medimmune, Llc Methods for purification of viruses
EP2344634A4 (en) 2008-09-24 2012-08-29 Medimmune Llc METHODS OF CELL CULTURE, AND PROPAGATION AND PURIFICATION OF VIRUSES
CA2741961A1 (en) 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
CA2778332A1 (en) * 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
US9426989B2 (en) 2010-05-06 2016-08-30 Novartis Ag Organic peroxide compounds for microorganism inactivation
CN103025350A (zh) 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法
WO2011151723A2 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
WO2012023044A1 (en) 2010-08-20 2012-02-23 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
SG192821A1 (en) * 2011-02-17 2013-09-30 Boehringer Ingelheim Vetmed Commercial scale process for production of prrsv
CA2829774C (en) 2011-03-14 2019-09-24 National Research Council Of Canada Method of viral production in cells
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
EP2822585B1 (en) 2012-03-06 2017-05-17 Janssen Vaccines & Prevention B.V. Improved vaccination against influenza
WO2014031480A1 (en) * 2012-08-24 2014-02-27 Xcellerex, Inc. Virus purification and formulation process
KR101370512B1 (ko) * 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
KR102790570B1 (ko) 2015-07-07 2025-04-04 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
CN105561317B (zh) * 2015-12-22 2018-03-20 肇庆大华农生物药品有限公司 重组伪狂犬病病毒疫苗耐热冻干保护剂及其制备方法
CN108239619A (zh) * 2016-12-23 2018-07-03 甘肃健顺生物科技有限公司 悬浮mdck细胞相关疫苗生产的二阶培养工艺技术
CN108570444A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 St细胞驯化悬浮方法和二阶病毒生产工艺
CN108570445A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 Pk15细胞驯化悬浮方法和二阶病毒生产工艺
CN108570454A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 Mdbk驯化悬浮方法和二阶病毒生产工艺
EP4061930A1 (en) 2019-11-18 2022-09-28 Seqirus Pty Ltd Method for producing reassortant influenza viruses
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037000A1 (en) * 1996-04-01 1997-10-09 Chiron Behring Gmbh & Co. Animal cells and processes for the replication of influenza viruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990072201A (ko) * 1996-10-18 1999-09-27 무타이 마사히꼬 로타바이러스 항원, 로타바이러스 감염증에 대한백신 및 진단제와 항원 제조방법
GB9915413D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Propagation method
KR100797547B1 (ko) * 2000-03-03 2008-01-24 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037000A1 (en) * 1996-04-01 1997-10-09 Chiron Behring Gmbh & Co. Animal cells and processes for the replication of influenza viruses

Also Published As

Publication number Publication date
HK1062029A1 (zh) 2004-10-15
SI1427817T1 (sl) 2010-08-31
DK1427817T3 (da) 2010-08-23
CY1110716T1 (el) 2015-06-10
DE10144903A1 (de) 2003-03-27
ES2345606T3 (es) 2010-09-28
BR0212469A (pt) 2004-08-24
ATE466932T1 (de) 2010-05-15
PT1427817E (pt) 2010-08-10
US20050118698A1 (en) 2005-06-02
AU2002338666B2 (en) 2008-11-20
JP2005502357A (ja) 2005-01-27
CA2456561A1 (en) 2003-03-20
EP1427817B1 (de) 2010-05-05
WO2003023025A1 (de) 2003-03-20
DE50214416D1 (de) 2010-06-17
KR20050027164A (ko) 2005-03-17
NZ532203A (en) 2005-04-29
EP1427817A1 (de) 2004-06-16
JP2010246559A (ja) 2010-11-04

Similar Documents

Publication Publication Date Title
KR100968141B1 (ko) 세포 배양물에서 바이러스의 증식 방법
US10329536B2 (en) Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture
JP5264843B2 (ja) 細胞培養におけるインフルエンザウイルスの複製の方法、および本方法によって入手可能なインフルエンザウイルス
JP4243349B2 (ja) インフルエンザウイルスの複製のための動物細胞および方法
HK1062029B (en) Multiplication of viruses in a cell culture
HK1062030B (en) Methods for the industrial production of vaccines
HK1149046A (en) Method for manufacturing an active component of a medicine or diagnosis agent in mdcj cell suspension culture

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040312

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070907

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090624

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20100407

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20100629

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20100630

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20130604

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20130604

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20140609

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20140609

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20150602

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20150602

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20160527

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20160527

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20170601

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20170601

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20180529

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20180529

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20190530

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20190530

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20200528

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20210527

Start annual number: 12

End annual number: 12

PC1801 Expiration of term

Termination date: 20230311

Termination category: Expiration of duration